PYXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pyxis Oncology Inc (PYXS) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are neutral, options data shows low sentiment, and financial performance remains weak. While analysts maintain positive ratings with adjusted price targets, the lack of significant positive catalysts and the absence of strong trading signals suggest holding off on investment for now.
The MACD is slightly positive at 0.0221, indicating weak bullish momentum, but it is contracting. RSI is neutral at 33.851, and moving averages are converging, signaling no clear trend. Support is at 1.37, and resistance is at 1.523, with the current price of 1.3585 trading near support levels.
Analysts have maintained positive ratings with adjusted price targets, citing consistent efficacy and manageable safety profiles in clinical trials.
The stock has a high adverse effect and discontinuation rate in trials, a smaller-than-expected data update, and weak financial performance. Additionally, no significant hedge fund or insider trading trends were observed, and there is no recent news or congress trading data.
In Q3 2025, revenue remained at 0 with no growth. Net income improved slightly to -22,003,000 (up 3.77% YoY), and EPS remained at -0.35. Gross margin increased to 100%, but overall financials are weak.
Analysts have mixed updates: RBC Capital lowered the price target to $5 from $8 but maintained an Outperform rating, citing potential for optimization in trials. H.C. Wainwright raised the price target to $7 from $5, citing consistent efficacy and manageable safety profiles.
